10% erbij op dit nieuws:
Stanford University Publishes New Data on Immuno-potential of Hemispherx's Ampligen(R)
May Enhance Bioactivity of Cancer Immunotherapies
Press Release Source: Hemispherx Biopharma, Inc. On Thursday January 28, 2010, 1:36 pm
PHILADELPHIA, Jan. 28, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the “Company”), announced the publication of a peer-reviewed article providing study data on Ampligen® [rintatolimod; poly(I)·poly(C12,U)] , an experimental therapeutic, in the current issue of the American Journal of Obstetrics and Gynecology (Epub ahead of print Jan 15, 2010 vol 202). The report, whose lead author is Dr. Jonathan S. Berek, Professor and Chair, Obstetrics and Gynecology, Stanford University School of Medicine, and colleagues, further details results presented at the Pacific Coast Oncology Gynecology Society Meeting, La Jolla, California, on October 1, 2009. Entitled “Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy,” the article discusses the value of stimulating a periodic “danger signal” with a TLR3 agonist such as poly(I)·poly(C12,U) as part of immunotherapeutic cancer treatment regimens, and suggests such regimens may have broad potential application to boost the effects of many immunotherapies of cancer.
The authors concluded that “poly(I)·poly(C12,U) shows promise as a potential agent for selective enhancement of effect with currently available and future cancer immunotherapies.” The authors also provided the following experimental observations in this report: “Dendritic cells are matured and T-cell stimulation is enhanced in the presence of poly(I)·poly(C12,U) . In addition, poly(I)·poly(C12,U) induced the release of proinflammatory chemokines and cytokines. Prostate-specific antigen-specific T-cell and antibody responses were enhanced significantly in a BALB/c prostate-specific antigen transgenic mouse model. Finally, rituximab [Rituxan®]-mediated antibody-dependent cellular cytotoxicity against tumor targets was improved significantly by the addition of poly(I)·poly(C12,U) .”
According to the authors, “immunotherapy of cancer holds the promise of disease-specific intervention without the toxicity that is associated with traditional therapeutic modalities."
The reported study was supported by an Ovarian Cancer Research Fund COGI Grant, Advanced Immune Therapeutics, Hemispherx Biopharma, and grants from the National Institute of Health (Grants CA 33399, CA 34233), the Ruth Kirschstein Award (Grant 5 T32 AI07290, and the Ruth L. Kirschstein Award (Grant F32 DKO78416).
Ampligen® (poly(I)·poly(C12,U)), an experimental immunotherapeutic, is also being studied as an influenza vaccine enhancer (Japanese National Institute of Infectious Diseases) and as potential monotherapy for chronic fatigue syndrome (CFS).